I think maybe the potency was fine, but as Stellow suggests, maybe the dosing was too low? They used the GVHD dosing because they thought the data generated from the ARDS trial might help with the GVHD submission.
Whatever the new assay data is, I suspect MSB has the data to show the product for the ARDS trial was sufficiently potent, as will be the stock to be used after we receive our BLA for GVHD.
I think maybe the potency was fine, but as Stellow suggests,...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.030(2.60%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.17 | $5.109M | 4.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 114618 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 3469 | 4 |
View Market Depth
| Last trade - 11.10am 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.18 |
Change
0.030 ( 2.53 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.17 | 836796 | ||
| Last updated 11.26am 07/05/2024 ? | |||||
| MSB (ASX) Chart |